Video

Dr. Ghamande Discusses GOG/NRG 0265 Study in Cervical Cancer

Author(s):

Sharad Ghamande, MD

In Partnership With:

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

Sharad Ghamande, MD, associate professor, Georgia Cancer Center, Augusta University, discusses the GOG/NRG-0265 study in cervical cancer.

The phase II GOG/NRG-0265 study sought to identify pre-treatment baseline levels of serum proteins to establish overall survival benefit for patients with persistent or recurrent metastatic carcinoma of the cervix treated with axalimogene filolisbac.

Related Videos
Albert Grinshpun, MD, MSc, head, Breast Oncology Service, Shaare Zedek Medical Center
Erica L. Mayer, MD, MPH, director, clinical research, Dana-Farber Cancer Institute; associate professor, medicine, Harvard Medical School
Mariya Rozenblit, MD, assistant professor, medicine (medical oncology), Yale School of Medicine
Maxwell Lloyd, MD, clinical fellow, medicine, Department of Medicine, Beth Israel Deaconess Medical Center
Tracy George, MD
Elias Jabbour, MD
Bently P. Doonan, MD
Eytan M. Stein, MD
Azka Ali, MD, medical oncologist, Cleveland Clinic Taussig Cancer Institute
Hope S. Rugo, MD, FASCO, Winterhof Family Endowed Professor in Breast Cancer, professor, Department of Medicine (Hematology/Oncology), director, Breast Oncology and Clinical Trials Education; medical director, Cancer Infusion Services; the University of California San Francisco Helen Diller Family Comprehensive Cancer Center
Related Content
Stephanie Gaillard, MD, PhD, of Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
December 10th 2024

New ADCs Join NCCN Guidelines for Gynecologic Cancers Representing Step Forward

Bradley J. Monk, MD, FACOG, FACS; Paolo Tarantino, MD
January 11th 2024

Monk and Tarantino Describe the Investigation of B7-H4 Vedotin–Directed ADCs in Gynecologic and Breast Cancers

FDA
December 5th 2024

FDA Grants Fast Track Designation to CRB-701 in Relapsed/Refractory Cervical Cancer

R. Wendel Naumann, MD
October 26th 2023

Naumann Discusses Notable Research Efforts in Endometrial Cancer

Katsyarina – stock.adobe.com
December 3rd 2024

NMPA Grants Conditional Approval to Fruquintinib Plus Sintilimab for pMMR Endometrial Cancer

November Recap
December 2nd 2024

Revisit Every OncLive On Air Episode From November 2024